It has been shown that two weeks of treatment with the selective COX-2 inhibitor Rofecoxib resulted in the increase of caspase-3 cleavage, decline of B-cell lymphoma 2 (Bcl-2), and survivin expression in tumors, and in parallel, decreased gastrin level in the plasma of GC patients [133]. Here, BCL2 is linked to gastric cancer.